Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients
Background: The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/1756284819858511 |
| _version_ | 1818504668937977856 |
|---|---|
| author | Hideki Mori Hidekazu Suzuki Fumio Omata Tatsuhiro Masaoka Daisuke Asaoka Kohei Kawakami Shigeaki Mizuno Naoto Kurihara Akihito Nagahara Nobuhiro Sakaki Masayoshi Ito Yo Kawamura Masayuki Suzuki Yuji Shimada Hitoshi Sasaki Takeshi Matsuhisa Akira Torii Toshihiro Nishizawa Tetsuya Mine Toshifumi Ohkusa Takashi Kawai Kengo Tokunaga Shin’ichi Takahashi |
| author_facet | Hideki Mori Hidekazu Suzuki Fumio Omata Tatsuhiro Masaoka Daisuke Asaoka Kohei Kawakami Shigeaki Mizuno Naoto Kurihara Akihito Nagahara Nobuhiro Sakaki Masayoshi Ito Yo Kawamura Masayuki Suzuki Yuji Shimada Hitoshi Sasaki Takeshi Matsuhisa Akira Torii Toshihiro Nishizawa Tetsuya Mine Toshifumi Ohkusa Takashi Kawai Kengo Tokunaga Shin’ichi Takahashi |
| author_sort | Hideki Mori |
| collection | DOAJ |
| description | Background: The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In this study, we examined the trend of the eradication rate of H. pylori in the metropolitan area and examined factors concerning successful eradication. Methods: We collected data from 20 hospitals in the Tokyo metropolitan area on patients who received first-line eradication therapy with a proton-pump inhibitor (PPI)/P-CAB, amoxicillin, and clarithromycin for 1 week and second-line eradication therapy with a PPI/P-CAB, amoxicillin, and metronidazole for 1 week from 2013 to 2018. The annual eradication rate and associated factors for successful eradication were analyzed. Results: We collected data of 4097 and 3572 patients in the first- and second-line eradication therapies, respectively. The eradication rate decreased from 2013 to 2014 and increased again from 2015 to 2018 with the first-line therapy [the eradication rates in 2013, 2014, 2015, 2016, 2017 and 2018 were 71.8%, 63.7%, 78.5%, 84.6%, 89.7 and 90.1%, respectively, in the per protocol (PP)]. The second-line eradication rates were 90.0%, 82.6%, 88.8%, 87.5%, 91.8% and 90.1% in 2013, 2014, 2015, 2016, 2017 and 2018, respectively, in PP. Vonoprazan was an independent factor for successful eradication in not only first-line, but also second-line eradication. Age over 75 years was an independent factor for eradication failure in both first- and second-line eradication therapies. Conclusion: The eradication rate improved from 2015 to 2018 with the first-line therapy because of the introduction of vonoprazan in the market. The eradication rates with first- and second-line regimens in elderly patients were lower than those in younger patients. |
| first_indexed | 2024-12-10T21:40:11Z |
| format | Article |
| id | doaj.art-de3730de68e246728f2350f322a32ebd |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-12-10T21:40:11Z |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-de3730de68e246728f2350f322a32ebd2022-12-22T01:32:31ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482019-07-011210.1177/1756284819858511Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patientsHideki MoriHidekazu SuzukiFumio OmataTatsuhiro MasaokaDaisuke AsaokaKohei KawakamiShigeaki MizunoNaoto KuriharaAkihito NagaharaNobuhiro SakakiMasayoshi ItoYo KawamuraMasayuki SuzukiYuji ShimadaHitoshi SasakiTakeshi MatsuhisaAkira ToriiToshihiro NishizawaTetsuya MineToshifumi OhkusaTakashi KawaiKengo TokunagaShin’ichi TakahashiBackground: The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In this study, we examined the trend of the eradication rate of H. pylori in the metropolitan area and examined factors concerning successful eradication. Methods: We collected data from 20 hospitals in the Tokyo metropolitan area on patients who received first-line eradication therapy with a proton-pump inhibitor (PPI)/P-CAB, amoxicillin, and clarithromycin for 1 week and second-line eradication therapy with a PPI/P-CAB, amoxicillin, and metronidazole for 1 week from 2013 to 2018. The annual eradication rate and associated factors for successful eradication were analyzed. Results: We collected data of 4097 and 3572 patients in the first- and second-line eradication therapies, respectively. The eradication rate decreased from 2013 to 2014 and increased again from 2015 to 2018 with the first-line therapy [the eradication rates in 2013, 2014, 2015, 2016, 2017 and 2018 were 71.8%, 63.7%, 78.5%, 84.6%, 89.7 and 90.1%, respectively, in the per protocol (PP)]. The second-line eradication rates were 90.0%, 82.6%, 88.8%, 87.5%, 91.8% and 90.1% in 2013, 2014, 2015, 2016, 2017 and 2018, respectively, in PP. Vonoprazan was an independent factor for successful eradication in not only first-line, but also second-line eradication. Age over 75 years was an independent factor for eradication failure in both first- and second-line eradication therapies. Conclusion: The eradication rate improved from 2015 to 2018 with the first-line therapy because of the introduction of vonoprazan in the market. The eradication rates with first- and second-line regimens in elderly patients were lower than those in younger patients.https://doi.org/10.1177/1756284819858511 |
| spellingShingle | Hideki Mori Hidekazu Suzuki Fumio Omata Tatsuhiro Masaoka Daisuke Asaoka Kohei Kawakami Shigeaki Mizuno Naoto Kurihara Akihito Nagahara Nobuhiro Sakaki Masayoshi Ito Yo Kawamura Masayuki Suzuki Yuji Shimada Hitoshi Sasaki Takeshi Matsuhisa Akira Torii Toshihiro Nishizawa Tetsuya Mine Toshifumi Ohkusa Takashi Kawai Kengo Tokunaga Shin’ichi Takahashi Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients Therapeutic Advances in Gastroenterology |
| title | Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients |
| title_full | Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients |
| title_fullStr | Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients |
| title_full_unstemmed | Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients |
| title_short | Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients |
| title_sort | current status of first and second line eradication therapy in the metropolitan area a multicenter study with a large number of patients |
| url | https://doi.org/10.1177/1756284819858511 |
| work_keys_str_mv | AT hidekimori currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT hidekazusuzuki currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT fumioomata currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT tatsuhiromasaoka currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT daisukeasaoka currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT koheikawakami currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT shigeakimizuno currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT naotokurihara currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT akihitonagahara currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT nobuhirosakaki currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT masayoshiito currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT yokawamura currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT masayukisuzuki currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT yujishimada currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT hitoshisasaki currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT takeshimatsuhisa currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT akiratorii currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT toshihironishizawa currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT tetsuyamine currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT toshifumiohkusa currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT takashikawai currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT kengotokunaga currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients AT shinichitakahashi currentstatusoffirstandsecondlineeradicationtherapyinthemetropolitanareaamulticenterstudywithalargenumberofpatients |